Search research articles
Contact Us
Filters
Showing results (1-10 of 150) with videos related to
Page
of 15
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 28, 2020
Response to Letter to Editor by Cornelissen et al
Raffit Hassan, Markku Miettinen
Hematology/Oncology Clinics of North America
|
December 6, 2005
Nonpleural mesotheliomas: mesothelioma of the peritoneum, tunica vaginalis, and pericardium
Raffit Hassan, Richard Alexander
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 24, 2022
Somatic BAP1 Loss as a Predictive Biomarker of Overall Survival in Patients With Malignant Pleural Mesothelioma Treated With Chemotherapy
Azam Ghafoor, Raffit Hassan
The Lancet. Oncology
|
July 4, 2012
Immunotherapies for non-small-cell lung cancer and mesothelioma
Anish Thomas, Raffit Hassan
Cancer Research
|
May 15, 2014
Discovery of mesothelin and exploiting it as a target for immunotherapy
Ira Pastan, Raffit Hassan
The Lancet. Oncology
|
July 22, 2017
CTLA-4 blockade in mesothelioma: ineffective or reason for optimism?
Anish Thomas, Raffit Hassan
European Journal of Cancer (Oxford, England : 1990)
|
October 20, 2007
Mesothelin targeted cancer immunotherapy
Raffit Hassan, Mitchell Ho
Oncology (Williston Park, N.Y.)
|
February 19, 2013
Clinical and pathological features are still the best determinants of prognosis in mesothelioma
Andrew C Miller, Raffit Hassan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2015
New Life for Immunotoxin Cancer Therapy
Raffit Hassan, Christine Alewine, Ira Pastan
Lung Cancer (Amsterdam, Netherlands)
|
January 30, 2013
Farletuzumab in lung cancer
Anish Thomas, Julia Maltzman, Raffit Hassan
Page
of 15
Search research articles
Search
Showing results (1-10 of 150) with videos related to
Sort By:
Page
of 15
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 28, 2020
Response to Letter to Editor by Cornelissen et al
Raffit Hassan, Markku Miettinen
Hematology/Oncology Clinics of North America
|
December 6, 2005
Nonpleural mesotheliomas: mesothelioma of the peritoneum, tunica vaginalis, and pericardium
Raffit Hassan, Richard Alexander
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 24, 2022
Somatic BAP1 Loss as a Predictive Biomarker of Overall Survival in Patients With Malignant Pleural Mesothelioma Treated With Chemotherapy
Azam Ghafoor, Raffit Hassan
The Lancet. Oncology
|
July 4, 2012
Immunotherapies for non-small-cell lung cancer and mesothelioma
Anish Thomas, Raffit Hassan
Cancer Research
|
May 15, 2014
Discovery of mesothelin and exploiting it as a target for immunotherapy
Ira Pastan, Raffit Hassan
The Lancet. Oncology
|
July 22, 2017
CTLA-4 blockade in mesothelioma: ineffective or reason for optimism?
Anish Thomas, Raffit Hassan
European Journal of Cancer (Oxford, England : 1990)
|
October 20, 2007
Mesothelin targeted cancer immunotherapy
Raffit Hassan, Mitchell Ho
Oncology (Williston Park, N.Y.)
|
February 19, 2013
Clinical and pathological features are still the best determinants of prognosis in mesothelioma
Andrew C Miller, Raffit Hassan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2015
New Life for Immunotoxin Cancer Therapy
Raffit Hassan, Christine Alewine, Ira Pastan
Lung Cancer (Amsterdam, Netherlands)
|
January 30, 2013
Farletuzumab in lung cancer
Anish Thomas, Julia Maltzman, Raffit Hassan
Page
of 15